

Proteomic and functional insights into spinal neuroimmune maladaptation: dual-level modulation of mast cell-neural crosstalk by ultramicronized palmitoylethanolamide

Alessandra Toti

`alessandra.toti@unifi.it`

University of Florence

Maria Giovanna Cataldi

University of Florence

Laura Micheli

University of Florence

Elena Lucarini

University of Florence

Francesco Margiotta

University of Florence

Daniel Venturi

University of Florence

Gilda Aiello

Telematic University San Raffaele

Alfonsina D'Amato

University of Milan

Tommaso Mello

University of Florence

Carla Ghelardini

University of Florence

Lorenzo Di Cesare Mannelli

University of Florence

Research Article

Keywords:

Posted Date: October 23rd, 2026

DOI: <https://doi.org/10.21203/rs.3.rs-10892364/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.
[Read Full License](#)

Additional Declarations: No competing interests reported.

Proteomic and functional insights into spinal neuroimmune maladaptation: dual-level modulation of mast cell-neural crosstalk by ultramicronized palmitoylethanolamide

Alessandra Toti^{1*^}; Maria Giovanna Cataldi^{1*}, Laura Micheli¹; Elena Lucarini¹; Francesco Margiotta^{1,2}; Daniel Venturi^{1,3}; Gilda Aiello⁴, Alfonsina D'Amato⁵; Tommaso Mello⁶; Carla Ghelardini¹; Lorenzo Di Cesare Mannelli¹.

¹*Department of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and Toxicology Section, University of Florence, Florence, Italy*

²*European Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy*

³*Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, United Kingdom.*

⁴*Department of Human Science and Quality of Life Promotion, Telematic University San Raffaele, 00166 Rome*

⁵*Department of Pharmaceutical Sciences, University of Milan, Milan, Italy*

⁶*Department of Biomedical Clinical and Experimental Sciences "Mario Serio" - Clinical Gastroenterology Unit - University of Florence, Florence, Italy*

*These authors contributed equally

[^]Corresponding author: alessandra.toti@unifi.it; +39 0552758395; Viale G. Pieraccini 6, 50139, Firenze (FI), Italy.

32 **Abstract**

33 Repeated morphine administration drives spinal neuroimmune mechanisms contributing to analgesic
34 tolerance and hyperalgesia. We investigated the contribution of mast cell-derived mediators to spinal
35 neuroinflammation and the homeostatic effects of ultramicrosized palmitoylethanolamide (PEA)
36 using rat organotypic spinal cord slice cultures. Slices exposed to morphine were treated with
37 conditioned medium from activated RBL-2H3 mast cells. Mast cell-derived conditioned medium
38 induced a robust neuroinflammatory response, upregulating IL-6, IL-1 β , CCL2, and PTX3
39 expression, and markedly enhancing the release of the pro-nociceptive neuropeptide CGRP. These
40 alterations were accompanied by reduced neuronal marker expression and impaired astrocytic
41 reactivity in the spinal dorsal horn. Notably, upstream mast cell pretreatment with PEA modified their
42 secretory activity, blunting subsequent spinal inflammatory cascades. Quantitative proteomic
43 analysis revealed that conditioned medium derived from PEA-treated RBL-2H3 cells extensively
44 reshaped the spinal microenvironment, rescuing extracellular matrix components (such as collagen
45 VI), downregulating neurodegenerative markers (including SIRT2 and BIN1), and inducing
46 protective regulators like LGALS1. Downstream tissue-level application of ultramicrosized PEA
47 directly to the spinal slices replicated these beneficial actions, significantly attenuating inflammatory
48 transcription and CGRP release while restoring neuronal and astrocytic homeostatic profiles.
49 Collectively, these findings suggest that mast cell-derived factors promote spinal neuroimmune
50 maladaptation, which is effectively countered by ultramicrosized PEA via a dual-level mechanism
51 acting on both the mast cell secretome and the spinal tissue interface. This integrated approach offers
52 a promising translational strategy to preserve opioid efficacy and mitigate central sensitization.

53

54 **Highlights**

- 55 • Mast cell-derived mediators induce neuroinflammatory and pro-nociceptive
56 signaling in spinal cord slices.
- 57 • PEA reprograms mast cell secretory activity and reduces inflammatory signaling.

- PEA preserves neuronal integrity and modulates astrocyte responses in mast cell-driven inflammation.

1. Introduction

Pain is a complex sensory and emotional experience associated with actual or potential tissue damage and involves coordinated activity across peripheral nociceptors, spinal dorsal horn circuits and supraspinal networks [1–3]. Beyond neuronal mechanisms, increasing evidence indicates that immune and glial cells contribute substantially to pain modulation through neuroimmune signaling processes that enhance neuronal excitability and promote central sensitization within the spinal cord [4].

Opioid analgesics remain the main pharmacological option for severe pain, acting predominantly through μ -opioid receptor signaling to inhibit nociceptive transmission at spinal and supraspinal levels [5]. However, repeated opioid exposure frequently leads to analgesic tolerance and opioid-induced hyperalgesia, limiting long-term therapeutic efficacy [6]. In addition to classical receptor desensitization mechanisms, opioid tolerance is increasingly recognized as a neuroimmune phenomenon. Morphine activates glial cells and inflammatory signaling pathways within the spinal cord, creating a permissive environment that reduces analgesic responsiveness and promotes maladaptive plasticity [4,7,8].

Among the immune components involved in neuroimmune regulation, mast cells are emerging as important modulators of nervous system function. Located at neurovascular and meningeal interfaces, mast cells release cytokines, chemokines and proteases capable of influencing neuronal excitability, glial activation and extracellular matrix organization [9,10]. Evidence suggests that mast cell-derived mediators contribute to spinal neuroinflammation and pain amplification, highlighting a bidirectional crosstalk between mast cells and neural tissue that may also participate in opioid maladaptation [11,12].

N-palmitoylethanolamine (PEA) is an endogenous lipid mediator with anti-inflammatory and anti-

84 hyperalgesic properties, acting primarily as a homeostatic regulator of non-neuronal cell activity,
85 including mast cells and glia [13]. Due to its highly lipophilic nature and poor water solubility, native
86 PEA exhibits low dissolution rates and limited gastrointestinal absorption. To overcome these
87 pharmacokinetic limitations, technological modification through jet milling is required to reduce
88 particle size, thereby increasing its surface area and oral bioavailability [14,15]. Consequently,
89 ultramicrosized PEA displays improved bioavailability and tissue distribution compared with native
90 PEA, reaching central nervous system structures such as the spinal cord [16]. Preclinical studies have
91 shown that ultramicrosized PEA prolongs morphine analgesia and delays tolerance development
92 during repeated opioid administration [17]. Moreover, recent evidence indicates that it can regulate
93 mast cell degranulation and modify mast cell-astrocyte communication, supporting the hypothesis
94 that its beneficial actions involve modulation of mast cell-nervous tissue interactions [18,19].
95 To investigate neuroimmune mechanisms in a multicellular context that preserves tissue architecture
96 and cellular interactions, organotypic spinal cord slice cultures represent a valuable *ex vivo* model
97 bridging simplified *in vitro* systems and *in vivo* conditions [20,21]. These preparations maintain
98 neuron-glia communication and allow controlled manipulation of inflammatory and pharmacological
99 stimuli within intact spinal circuitry.
100 In the present study, we investigated whether ultramicrosized PEA modulates neuroinflammatory
101 and pro-nociceptive signaling induced by mast cell mediators and morphine within organotypic spinal
102 cord slices, with particular focus on the functional and molecular consequences of mast cell-nervous
103 tissue crosstalk.

104

105 **2. Material and methods**

106 *2.1 Study approval*

107

108 All animal manipulations were carried out according to the Directive 2010/63/EU of the European
109 parliament and of the European Union council (22 September 2010) on the protection of animals used

110 for scientific purposes and in compliance with the International Association for the Study of Pain
111 (IASP) guidelines.

112 The ethical policy of the University of Florence complies with the Guide for the Care and Use of
113 Laboratory Animals of the US National Institutes of Health (NIH Publication No. 85-23, revised
114 1996; University of Florence assurance number: A5278-01).

115 Formal approval to conduct the experiments described was obtained from the Italian Ministry of
116 Health (No. 17.E9C.N.NOV) and the Animal Subjects Review Board of the University of Florence.
117 Experiments involving animals have been reported according to ARRIVE guidelines [22]. All efforts
118 were made to minimize animal suffering and to reduce the number of animals used.

119 *2.2 Preparation of rat organotypic spinal cord slice cultures*

120 Organotypic spinal cord slices were prepared according to Toti et al. (2025)[23]. Briefly, spinal cords
121 were removed from 4- to 6-day old male and female Sprague Dawley rat pups (Envigo, Varese, Italy)
122 and exposed. Transverse slices (420 μm) were prepared using a McIlwain tissue chopper and
123 transferred onto 30-mm diameter semiporous membranes inserts (Millicell-CM PICM03050;
124 Millipore, Italy), which were placed in six well tissue culture plates containing 1.2 mL medium per
125 well. The culture medium consisted of 50% Minimal Essential Medium (MEM), 25% Donor Horse
126 Serum Heat-Inactivated, 25% Hanks' balanced salt solution (HBSS), 5 mg/mL glucose, 2 mM L-
127 glutamine, 3.75 mg/mL amphotericin B and 1% penicillin (100 U/mL) and streptomycin (100
128 $\mu\text{g/mL}$). Slices were maintained at 37 °C in an incubator in an atmosphere of humidified air and 5%
129 CO₂ for 14 days. During *in vitro* maturation, the slices reduced their initial thickness while
130 maintaining their original structural integrity [23]. Prior to experiments, all the slices were screened
131 for viability by phase-contrast microscopy analysis; slices displaying signs of neurodegeneration
132 were discarded from the study (exclusion criteria).

133

134 *2.3 Organotypic spinal cord cultures treatments*

135 Rat basophilic leukemia (RBL-2H3) mast cell line was used. RBL-2H3 cells were pre-sensitized with
 136 anti-dinitrophenyl (DNP)-IgE (50 ng/mL) for 18 h in the absence (untreated) or presence of
 137 ultramicronized palmitoylethanolamide (PEA, 100 μ M). The following day, cells were washed to
 138 remove PEA and subsequently stimulated with dinitrophenyl-bovine serum albumin (DNP-BSA; 625
 139 ng/mL) for 24 h to induce degranulation. At the end of stimulation, culture media were collected and
 140 used as conditioned media (c.m.).

141 In parallel, organotypic spinal cord slices were exposed to morphine (30 μ M) for 48 h. Following
 142 morphine treatment, slices were incubated for 6 h with c.m. derived from untreated and PEA-treated
 143 RBL-2H3 cells. Prior to application to spinal cord slices, the c.m. was diluted 1:2 with culture medium
 144 (Supplementary Fig. 1A).

145 For experiments assessing the direct effects of PEA on spinal cord tissue, slices were incubated with
 146 c.m. from untreated RBL-2H3 cells either alone or in combination with PEA (50 nM) for 6 h
 147 (Supplementary Fig. 1B).

148

149 2.4 RNA isolation, Reverse Transcription and RT-PCR

150 Total RNA was isolated from rat organotypic spinal cord slices using TRI Reagent (Merck, Milan,
 151 Italy). 500 ng of RNA was retrotranscribed using PrimeScriptTM RT reagent Kit with gDNA eraser.
 152 RT-PCR was performed using SsoAdvanced Universal SYBR⁺ Green Supermix following the
 153 thermal profile suggested by the kit. The primer used are reported in Table 1 (Invitrogen, Monza,
 154 Italy).

rCCL2	Fw: 5'-TCTTCCTCCACCACTATGCAGGTCTC-3' Rv: 5'-TCTTTGGGACACCTGCTGCTGGTG-3'
rPTX3	Fw: 5'-AAACTTCGCCTCTCCAGCAATGCATC-3' Rv: 5'-TGAACAGCTTGTCCCACTCCGAGTG-3'

rGFAP	Fw: 5'-CTGACACACGTTGTGTTCAAGCAGCC-3' Rv: 5'-CTGAAGGTTAGCAGAGTTGACAAGGG-3'
rSCL1A3	Fw: 5'-CAGTCATCGTCGGCCTCCTCATTC-3' Rv: 5'-CTGGTGATGCGTTTGTCCACACCATTG-3'

155

156 ***Table 1. List of forward and reverse primers used for RT-PCR***

157 The following validated primers were purchased from Bio-Rad: rIL-6 (qRnoCID0004680), rIL-1B
158 (qRnoCID0004680), rScl1a2 (qRnoCED0005967) and rβ2microglobulin as housekeeping
159 (qRnoCED0056999). The differential expression of the transcripts is normalized on the housekeeping
160 gene.

161 ***2.5 Biochemical analysis***

162 At the end of the treatments, the culture medium was collected for biochemical analysis.
163 Concentrations of calcitonin gene-related peptide (CGRP) were assessed by enzyme-linked
164 immunosorbent assay (ELISA) (Biomatik, Ontario, Canada. cod. EKF58049), according to the
165 manufacturer's instructions. Levels were normalized to cell protein concentrations quantified by BCA
166 assay (Merck, Milan, Italy). Control conditions in the absence of treatment were arbitrarily set as
167 100% and all results are expressed as percentage in comparison with the control.

168 ***2.6 Immunofluorescence staining in free-floating***

169 Organotypic spinal cord slice cultures were fixed and processed for immunofluorescence as previously
170 described by Toti et al. (2025)[23] with minor modifications. After fixation with cold 4%
171 paraformaldehyde at 4 °C overnight, slices were blocked in TBS containing 0.3% Triton X-100 and 10%
172 normal goat serum. Slices were incubated overnight at 4 °C with the following primary antibodies:
173 chicken anti-GFAP (1:1000; PA1-10004, Life Technologies, Monza, Italy), rabbit anti-NeuN (1:200;
174 GTX132974, Genetex, TX, USA), and rabbit anti-Iba1 (1:200; Wako Chemicals USA, VA, USA). This

175 was followed by incubation with Alexa Fluor 647 goat anti-chicken secondary antibody (1:1000; Life
176 Technologies, Monza, Italy) and Alexa Fluor 568 goat anti-rabbit secondary antibody (1:1000; Life
177 Technologies, Monza, Italy). Nuclei were counterstained with DAPI, and slices were mounted using
178 Fluoromount prior to imaging. Images were acquired using a motorized Leica DM6000 B fluorescence
179 microscope. Image analysis was performed using ImageJ software (NIH, Bethesda, MD, USA). GFAP
180 and NeuN fluorescence intensity was quantified from two fields per slice (8 or 15 slices total) using a
181 20× objective, while NeuN⁺ cell counts were obtained from four fields per slice (8 or 15 slices total)
182 using a 40× objective.

183

184 2.7 Secretome, proteome and bioinformatic analysis

185 Two complementary proteomic analyses were performed. Secretome analysis was carried out on
186 conditioned media collected from untreated and PEA-treated RBL-2H3 cells after 24 h of DNP-BSA
187 stimulation. In parallel, proteomic analysis was performed on organotypic spinal cord slices treated or
188 not with morphine and exposed to RBL-2H3 c.m. for 6 h; the c.m. was then replaced with fresh
189 medium, and the slices were collected the following day. Each lyophilized medium and each slice were
190 homogenized and tryptic digested as in D'Amato et al. (2020)[24]. The peptides were analyzed using
191 a Dionex Ultimate 3000 nano-LC system (Sunnyvale CA, USA) connected to Orbitrap Fusion™
192 Tribrid™ Mass Spectrometer (Thermo Scientific, Bremen, Germany) equipped with a nano-
193 electrospray ion source (nESI). Mobile phases were the following: 0.1% formic acid (FA) in water
194 (solvent A), 0.1% FA in acetonitrile (solvent B). The elution gradient consisted of 4-28% B for 90 min
195 and then 28-40% for 10 min, followed by 95% for the next 6 min to rinse the column [25]. The
196 instrumental raw files were processed by MaxQuant software v1.6.6.0 [26] set on Uniprot_Rat database
197 against the Andromeda search engine [24]. The quantification of peptides and related proteins for each
198 sample in biological replicate and technical triplicates was based on the LFQ intensities. The
199 interpretation and visualization of results obtained from MaxQuant software were performed by a two-

sample t-test using Perseus (v1.6.1.3, Max Planck Institute of Biochemistry, Germany). Statistical parameters ($p < 0.05$; $q < 0.05$, $q = \text{FDR adjusted } p\text{-value}$) were set to identify the differentially expressed proteins between samples ($\log_2$ ratio). Variability of biological replicates were measured using the scatter plot with Pearson correlation coefficient values of the LFQ intensities. The network protein analysis related to significantly altered proteins was carried out by Ingenuity Pathways Analysis (IPA) (last release; Qiagen) based on Gene Ontology database [25].

2.8 Cytotoxicity assay

For toxicity evaluation, the release of lactate dehydrogenase (LDH) into the culture media was determined using a Cytotoxicity Detection Kit (Roche 11644793001, Roche Diagnostics GmbH Roche Applied Science Mannheim, Germany) according to the manufacturer's protocol. Each value corresponds to a well, with five slices per transwell, and a total of six samples ($n=6$) were analyzed. LDH levels were normalized to cell protein concentrations, quantified by bicinchoninic acid (BCA) assay (Merck, Milan, Italy). Control conditions in the absence of treatment were arbitrarily set as 100%, and all results are expressed as percentage in comparison with the control.

2.9 Statistics

Results were expressed as a mean $\pm$ S.E.M., and statistical analysis was performed using ONE-way or TWO-way ANOVA. Bonferroni's post hoc test was applied for multiple comparisons. P values less than 0.05 were considered statistically significant. Data were analyzed using "Origin[®] 9.1" software.

3. Results

3.1 Ultramicronized PEA modulates morphine-induced neuroinflammatory gene expression via mast cell mediators in organotypic spinal cord cultures

Our previous work showed that ultramicronized palmitoylethanolamide (PEA; 100 μ M, 18 h) significantly modulates DNP-BSA-induced degranulation of the rat basophilic leukemia mast cell line RBL-2H3 (Toti et al., 2023). Secretome analysis further demonstrated that PEA reduces the release of several degranulation-associated and inflammatory mediators, including β -hexosaminidase, mast cell protease 2, GM2 activator protein, and the chemokine C-C motif chemokine ligand 2 (CCL2) (Supplementary Fig. 2 and Supplementary Tab. 1).

To investigate the functional consequences of mast cell signaling in a more integrated CNS context, particularly under opioid exposure, we employed rat organotypic spinal cord slice cultures, an *ex vivo* model that preserves cellular heterogeneity and neuroimmune interactions.

Preliminary experiments identified 30 μ M morphine as the highest concentration that did not compromise slice viability (Supplementary Fig. 3A).

Notably, while conditioned media (c.m.) from untreated RBL-2H3 cells induced significant cellular toxicity, indicated by LDH levels (Supplementary Fig. 3B), this effect was completely absent when c.m. was derived from mast cells treated with PEA. Therefore, to ensure uniform and non-toxic conditions across all experimental groups, all c.m. were diluted 1:2 prior to spinal cord slice application (Supplementary Fig. 3C).

Slices were exposed to morphine (30 μ M) for 48 h, followed by a 6-h incubation with c.m. derived from either untreated or PEA-treated RBL-2H3 cells (100 μ M PEA, 18 h). Gene expression of neuroinflammatory and glutamatergic markers was then assessed by RT-PCR.

In control slices treated with c.m. from untreated RBL-2H3 cells, the expression of the pro-inflammatory mediators interleukin-6 (IL-6), interleukin-1 β (IL-1 β), CCL2, and pentraxin-3 (PTX3) was significantly increased compared with control slices (Fig. 1A). A non-significant trend toward

250 increased expression of the glial glutamate transporter excitatory amino acid transporter 1 (EAAT1)
251 was also observed, whereas glial fibrillary acidic protein (GFAP) and excitatory amino acid
252 transporter 2 (EAAT2) expression remained unchanged (Fig. 1B).

253 Conditioned medium derived from PEA-pretreated RBL-2H3 cells significantly reduced the
254 expression of all the above-mentioned pro-inflammatory genes. EAAT1 expression also decreased
255 under this condition, reflecting an attenuation of reactive glial responses (Fig. 1A-B).

256 A comparable pattern was observed in morphine-treated slices. Exposure to c.m. from untreated RBL-
257 2H3 cells increased IL-6, IL-1 β , PTX3, and CCL2 expression compared with control, whereas c.m.
258 from PEA-pretreated cells attenuated these responses (Fig. 1A). In contrast, GFAP and EAAT2
259 expression showed a different profile: morphine-treated slices incubated with c.m. from untreated
260 RBL-2H3 cells displayed reduced expression of both genes compared to CTR, while treatment with
261 c.m. from PEA-pretreated cells significantly increased their expression (Fig. 1B).

262 Finally, a comparison between control slices and morphine-treated slices, both incubated with
263 untreated RBL-2H3-derived c.m., revealed a markedly higher IL-1 β expression in the morphine
264 group, suggesting an additive or synergistic interaction between morphine exposure and mast cell-
265 derived inflammatory signals.

266 Overall, these findings indicate that mast cell-derived soluble mediators strongly influence
267 neuroinflammatory and glutamatergic gene expression in spinal cord tissue. Moreover, PEA
268 pretreatment appears to reprogram mast cell signaling, reducing pro-inflammatory responses while
269 promoting astrocyte-associated homeostatic pathways, particularly in the context of morphine
270 exposure.

271

272




Figure 1. Ultramicronized PEA modulates neuroinflammatory and glutamatergic gene expression in organotypic spinal cord cultures. (A-B) Slices were treated with morphine (MOR, 30 μ M) for 48 h and subsequently incubated for 6 h with c.m. derived from RBL-2H3 cells stimulated with DNP-BSA (625 ng/mL) and either untreated or pretreated with ultramicronized PEA (100 μ M, 18 h). Data are presented as mean $\pm$ S.E.M. of three independent experiments. * P < 0.05, *** P < 0.001 vs CTR slices; ^ P < 0.05, ^^ P < 0.01, ^^P < 0.001 vs slices + c.m. untreated RBL; δ P < 0.01 MOR + c.m. untreated RBL vs CTR + c.m. untreated RBL.


3.2 Ultramicronized PEA modulates mast cell-mediated regulation of CGRP release in morphine-treated spinal cord slices

In order to assess pro-nociceptive signaling, calcitonin gene-related peptide (CGRP) release into the culture medium was measured by ELISA kit, under the same experimental conditions described above. Morphine exposure (30 μ M, 48 h) significantly reduced CGRP release from spinal cord slices compared with control conditions (Fig. 2). In control slices, incubation with c.m. from untreated RBL-2H3 cells significantly increased CGRP levels, indicating that mast cell-derived soluble mediators stimulate CGRP release in spinal tissue.

This effect was markedly attenuated by PEA-treatment of RBL-2H3 cells, suggesting that PEA down-modulates mast cell secretory activity and reduces the ability of mast cell mediators to promote CGRP release.

In morphine-treated slices, incubation with c.m. from untreated RBL-2H3 cells did not significantly

293 modify CGRP levels compared with morphine treatment alone. In contrast, exposure to c.m. derived
 294 from PEA-treated RBL-2H3 cells produced a further reduction in CGRP release.
 295 Overall, these findings indicate that mast cell-derived soluble factors regulate CGRP release in spinal
 296 cord tissue and that PEA pretreatment of mast cells modifies this signaling, limiting CGRP release
 297 under basal conditions and further enhancing the morphine-induced reduction of CGRP levels.



298
 299 **Figure 2. Mast cell-derived mediators and PEA regulate CGRP release in morphine-treated spinal cord slices.**
 300 CGRP release from rat organotypic spinal cord slice cultures exposed to mast cell-conditioned media under
 301 basal conditions or following morphine treatment. Slices were treated with morphine (30 μM) for 48 h and
 302 subsequently incubated for 6 h with c.m. derived from RBL-2H3 cells stimulated with DNP-BSA (625 ng/mL)
 303 and either untreated or pretreated with ultramicrosonized PEA (100 μM, 18 h). After treatments, the culture
 304 medium was replaced with fresh serum-free medium, and CGRP levels in the supernatant were measured
 305 following an 18 h collection period. CGRP release is expressed as percentage of control slices, which were
 306 arbitrarily set to 100%. Data represent the mean ± S.E.M. of three independent experiments in duplicates (n =
 307 6). ** $P < 0.01$ vs CTR slices; ^^^ $P < 0.001$ vs slices +c.m. untreated RBL.

308

309 3.3 Conditioned medium from ultramicrosonized PEA-treated mast cells enhances 310 neuronal survival and modulates astrocyte activation


311

312 To elucidate the underlying mechanisms, the response of neurons, astrocytes, and microglia in the
313 spinal cord slices was further investigated.

314 Neuronal integrity was evaluated by quantifying the number and fluorescence intensity of neuronal
315 nuclei-positive cells (NeuN⁺), a selective marker for mature neurons. As shown in Figure 3A, while
316 morphine treatment alone had no effect, exposing morphine-treated spinal cord slices to c.m. from
317 untreated RBL-2H3 cells significantly reduced the number of NeuN⁺ cells compared with control
318 slices. In contrast, incubation with c.m. derived from PEA-pretreated RBL-2H3 cells markedly
319 rescued this effect, increasing NeuN⁺ cell count in morphine-treated slices compared with those
320 exposed to untreated c.m. Similarly, exposure of control slices to PEA-treated c.m. resulted in a
321 higher number of NeuN⁺ cells compared with slices exposed to c.m. from untreated cells. Notably,
322 NeuN⁺ cell numbers in morphine-treated slices exposed to PEA-c.m. exceeded those observed in
323 control slices treated with the same medium. This indicates that the neuroprotective effect of
324 ultramicrosized PEA is particularly pronounced to counterbalance the marked neurotoxicity induced
325 by co-exposure to morphine and untreated RBL-2H3 cell c.m. Analysis of NeuN fluorescence
326 intensity (Fig. 3B) revealed no significant differences among most experimental groups; however, a
327 significant increase was detected in control slices treated with PEA-c.m. compared with untreated
328 control slices. Representative NeuN immunofluorescence images are shown in Figure 3C.

329 Astrocyte activation was assessed by measuring GFAP immunoreactivity. As shown in Figure 3D,
330 control slices incubated with c.m. from untreated RBL-2H3 cells showed reduced GFAP fluorescence
331 intensity which was rescued by c.m. from PEA-treated cells. Similarly, in morphine-treated slices,
332 PEA-c.m. significantly increased GFAP expression compared with untreated c.m. Notably,
333 morphine-treated slices exposed to c.m. derived from untreated RBL-2H3 cells displayed higher
334 GFAP intensity than their respective controls, suggesting a prominent morphine-induced astrocytic
335 response. Representative GFAP immunofluorescence images are shown in Figure 3E.

336 Microglial involvement was evaluated by measuring ionized calcium-binding adapter molecule 1
 337 (IBA-1) immunoreactivity. Nevertheless, no significant differences were detected among the
 338 experimental groups (Supplementary Fig.4).
 339



340
 341 **Figure 3. Effects of PEA-treated mast cell conditioned medium on neuronal viability and astrocyte activation.**
 342 *Immunofluorescence analysis of neuronal viability and astrocytic activation in rat organotypic spinal cord slice*

343 cultures exposed to mast cell-conditioned media under basal conditions or following morphine treatment. Slices
 344 were treated with morphine (30 μ M) for 48 h and subsequently incubated for 6 h with c.m. derived from RBL-
 345 2H3 mast cells stimulated with DNP-BSA (625 ng/mL) and either untreated or pretreated with ultramicrosonized
 346 PEA (100 μ M, 18 h). After 6 h of c.m. exposure, slices were washed and maintained in fresh medium for an
 347 additional 18 h before immunofluorescence analysis. (A) Quantification of NeuN⁺ cell number in the dorsal
 348 horn. (B) Quantification of NeuN fluorescence intensity in the dorsal horn. (C) Representative images of NeuN
 349 immunofluorescence. (D) Quantification of GFAP fluorescence intensity in the dorsal horn. (E) Representative
 350 images of GFAP immunofluorescence. Images were acquired using a 20 $\times$ objective; scale bar = 100 μ m. Data
 351 are expressed as mean $\pm$ S.E.M. of three independent experiments, with n = 8 slices per condition. **P<0.01 vs
 352 CTR slice. [^]P< 0.05; ^{^^}P< 0.001 vs slices +c.m. untreated RBL. ^{δδ}P< 0.01; ^{δδδ}P< 0.001 MOR +c.m. PEA treated
 353 RBL vs CTR slices +c.m. PEA treated RBL.

354

355 **3.4 Proteomic profiling of spinal cord slices exposed to ultramicrosonized PEA-modulated** 356 **mast cell conditioned medium**

357

358 To further characterize the molecular changes associated with mast cell-mediated signaling and PEA
 359 modulation, a quantitative proteomic analysis of the organotypic spinal cord slices was performed
 360 under the same experimental conditions described above. Various comparisons were conducted to
 361 evaluate the respective effects of morphine, degranulated RBL-2H3 medium and PEA.

362 In slices exposed to morphine, 18 proteins were significantly modulated (15 up-regulated and 3 down-
 363 regulated) compared with untreated controls (Fig. 4A). Among the up-regulated proteins, we
 364 identified pathways involved in inflammatory signaling and cytoskeletal remodeling including
 365 profilin-1 (PFN1), dynein light chain roadblock-type 1 (DYLRB1), ADP-ribosylation factor 4
 366 (ARF4), cold-inducible RNA-binding protein RBM3 (RBM3) and lamin-B2 (LMNB2). These
 367 findings indicate the activation of processes involved in cellular structural changes.

368 Exposure of control slices to c.m. from untreated RBL-2H3 cells changed the expression of 62
 369 proteins, with 25 being upregulated and 37 downregulated proteins (Fig. 4B). Under this condition,


370 proteins associated with inflammatory activation and neuroimmune signaling, such as cathepsin-D
371 (CTSD), biglycan (BGN), neurofilament light chain (NEFL), thioredoxin (TXN) and secretogranin-
372 2 (SCG2) were upregulated, reflecting a strong pro-inflammatory shift. Conversely, numerous
373 structural and myelin-associated proteins were downregulated, including collagen type I chains
374 (COL1A1, COL1A2), UDP-glycosyltransferase-8 (UGT8), ermin (ERMN), myelin basic protein
375 (MBP), myelin-associated oligodendrocyte basic protein (MOBP), ubiquitin C-terminal hydrolase L1
376 (UCHL1) and ubiquitin-conjugating enzyme E2N (UBE2N), pointing to weakened matrix stability
377 and altered myelin organization.

378 In the third comparison, c.m. from PEA-pretreated RBL-2H3 cells induced a proteomic response
379 involving 27 modulated proteins with 11 upregulated and 16 downregulated (Fig. 4C). This condition
380 was characterized by increased expression of glial fibrillary acidic protein (GFAP) and N-myc
381 downstream-regulated gene 2 (NDRG2), both associated with glial homeostasis. Conversely, we
382 observed a downregulation of proteins typically linked to stress and pro-inflammatory pathways, such
383 as ERO1-like protein alpha (ERO1L), glucose transporter GLUT1 (SLC2A1) and biglycan (BGN)
384 indicating that PEA modulates mast cell-derived signaling, shifting it toward a less inflamed tissue
385 environment.

386 Moreover, when morphine-treated slices were exposed to c.m from untreated RBL-2H3 cells, 46
387 proteins were significantly modulated (14 upregulated and 32 downregulated) (Fig. 4D). The
388 combination of morphine with mast-cell mediators exacerbated changes in extracellular matrix
389 (ECM) organization and innate immune signaling. Specifically, proteins such as Ras-related protein
390 Rap1b (RAP1B), Myc box-dependent interacting protein-1 (BIN1) and sirtuin-2 (SIRT2) were
391 increased. In contrast, several components involved in mitochondrial function, ECM stability,
392 synaptic regulation and cytoskeletal integrity, including transglutaminase-2 (TGM2), F-box only
393 protein-2 (FBXO2), Ubiquinol-Cytochrome C Reductase Core Protein 1 (UQCRC1), aldehyde
394 dehydrogenase 1A2 (ALDH1A2), collagen I and VI chains (COL1A1, COL6A 1,2,3), AHNAK
395 (AHNAK), calcyclin (S100A6) and fibrillin-1 (FBN1), were downregulated.

396 The final comparison, evaluating the effect of PEA-treated RBL-2H3 c.m. on morphine-exposed
397 slices, revealed the most extensive proteomic modulation, with 53 upregulated and 6 downregulated
398 proteins (Figure 4E). This condition recapitulated the main patterns identified in the earlier
399 comparisons, namely the downregulation of inflammatory mediators and the concomitant
400 upregulation of ECM components. Specifically, we observed a robust upregulation of collagen VI
401 chains (COL6A 1,2,3), biglycan (BGN), lumican (LUM), fibronectin-1 (FN1) and tenascin-C (TNC),
402 together with calcyclin (S100A6), AHNAK (AHNAK) and galectin-1 (LGALS1). Concurrently,
403 proteins associated with cellular stress and degeneration, such as sirtuin-2 (SIRT2) and myelin basic
404 protein (MBP), were reduced, suggesting that ultramicrosonicated PEA attenuates neuroinflammatory
405 damage and promotes tissue homeostasis.

406



407

408 *Figure 4. Differential proteomic modulation of organotypic spinal cord slices across experimental*
 409 *conditions.*

410 *Differentially expressed proteins identified by quantitative proteomic analysis in rat organotypic spinal cord*
 411 *slice cultures under the indicated experimental conditions. Each panel shows proteins significantly*
 412 *upregulated (green) or downregulated (red) in the specified comparison, based on a log2 ratio threshold of $\geq$*
 413 *0.56 or ≤ -0.56 with $p < 0.05$ (three biological replicates).*

414 *(A) Morphine-treated slices (MOR) versus untreated control slices (CTR).*

415 *(B) Control slices exposed to conditioned medium from untreated RBL-2H3 cells (CTR + c.m. untreated RBL)*
 416 *versus control slices.*

417 *(C) Control slices exposed to conditioned medium from ultramicronized PEA-treated RBL-2H3 cells (CTR +*
 418 *c.m. PEA-treated RBL) versus control slices exposed to conditioned medium from untreated RBL-2H3*
 419 *cells.*

420 *(D) Morphine-treated slices exposed to conditioned medium from untreated RBL-2H3 cells (MOR + c.m.*
 421 *untreated RBL) versus morphine-treated slices.*

422 *(E) Morphine-treated slices exposed to conditioned medium from ultramicronized PEA-treated RBL-2H3*
 423 *cells (MOR + c.m. PEA-treated RBL) versus morphine-treated slices exposed to conditioned medium from*
 424 *untreated RBL-2H3 cells.*

426 **3.5 Ultramicronized PEA directly suppresses pro-inflammatory gene expression in**

427 **organotypic spinal cord slices under mast cell-induced inflammation**

428

429 Building on the proteomic evidence indicating that PEA modulates inflammatory and tissue
 430 homeostasis-related pathways, we next investigated whether PEA could directly regulate
 431 neuroinflammatory responses in organotypic spinal cord slices. To model a mast cell-driven
 432 inflammatory environment, slices were exposed to c.m. diluted 1:2 from untreated RBL-2H3 cells.
 433 Specifically, the potential protective effects of PEA at the tissue level were evaluated by treating the
 434 slices for 6 h with untreated RBL-2H3 c.m., either alone or in combination with ultramicronized PEA
 435 (50 nM). This concentration was selected based on prior cytotoxicity assays to ensure tissue viability
 436 (Supplementary Fig. 5).

Quantitative RT-PCR analysis revealed that exposure to untreated RBL-2H3 c.m. markedly increased the expression of the pro-inflammatory genes IL-6, IL-1 β , CCL2, and PTX3 compared with control slices, confirming the strong neuroinflammatory impact of mast cell-derived soluble mediators (Fig. 5). Treatment with PEA alone did not significantly affect the expression of these markers compared with controls, except for a modest reduction in IL-6 levels. In contrast, co-treatment with PEA significantly suppressed the RBL-2H3 c.m.-induced upregulation of the inflammatory genes (Fig. 5). Together, these results demonstrate that direct application of ultramicrosized PEA to CNS tissue effectively counteracts mast cell-induced neuroinflammatory signaling, highlighting a dual modulatory role wherein PEA acts both at the level of mast cells and directly within the neural tissue.




Figure 5. Effects of direct PEA treatment on inflammatory gene expression in organotypic spinal cord slices exposed to mast cell-conditioned medium.

Gene expression analysis by RT-PCR in rat organotypic spinal cord slice cultures exposed to c.m. from untreated RBL-2H3 cells in the absence or presence of ultramicrosized PEA (50 nM). Slices were treated with RBL-2H3 c.m. alone or in combination with PEA for 6 h. mRNA levels of pro-inflammatory markers were quantified and normalized to housekeeping genes. mRNA values (gene expression) are reported as fold change relative to control slices, which were arbitrarily set to 1. Data represent the mean $\pm$ S.E.M. of three

455 independent experiments. $**P < 0.01$, $***P < 0.001$ vs CTR; $^{\wedge}P < 0.05$ vs slices treated with c.m. from
 456 untreated RBL-2H3.


457

458 3.6 Ultramicronized PEA modulates mast cell-mediated pro-nociceptive signaling in 459 organotypic spinal cord slices

460

461 To further investigate the pro-nociceptive effects of mast cell-derived mediators and the modulatory
 462 role of PEA, CGRP release was quantified under the same experimental conditions. As shown in
 463 Figure 6, treatment of organotypic spinal cord slices with PEA alone (50 nM) did not significantly
 464 affect CGRP release compared with control slices.

465 In contrast, exposure to c.m. from untreated RBL-2H3 cells resulted in a marked increase in CGRP
 466 release, reaching approximately 60% above control levels. Co-treatment with PEA significantly
 467 counteracted this increase, bringing CGRP release back to baseline levels.



468

469 **Figure 6. Effects of PEA on CGRP release induced by mast cell-conditioned medium in spinal cord slices.**


470 Quantification of CGRP release from rat organotypic spinal cord slice cultures exposed to c.m. from untreated
 471 RBL-2H3 cells in the absence or presence of ultramicronized PEA (50 nM). Slices were treated with RBL-2H3
 472 c.m. alone or in combination with PEA for 6 h. CGRP levels in the culture medium are expressed as mean $\pm$
 473 S.E.M. ($n = 8$). $*P < 0.05$ vs CTR; $^{\wedge}P < 0.01$ vs slices treated with c.m. untreated RBL.

474

3.7 Ultramicrosonicated PEA preserves neuronal integrity and modulates astrocyte reactivity in spinal cord slices exposed to conditioned medium from stimulated mast cells

To evaluate the effects of mast cell-induced inflammation and the modulatory action of PEA on neuronal markers, NeuN immunofluorescence was analyzed in organotypic spinal cord slices. Representative images (Figure 7C) revealed evident morphological differences in the dorsal horn region across experimental conditions. In particular, slices co-exposed to untreated RBL-2H3 c.m. and PEA displayed a more robust dorsal horn area compared with slices exposed to untreated c.m. alone, suggesting a role for PEA in preserving tissue architecture. This finding is consistent with the observation from NeuN⁺ cell quantification. As reported in figure 7A, while the untreated RBL-2H3 c.m. alone did not alter neuronal counts, a statistically significant increase in NeuN⁺ cell number was detected in slices co-exposed to PEA and untreated RBL-2H3 c.m. compared with both control slices and slices exposed to untreated c.m. alone. This overall trend was further corroborated by fluorescence intensity measurements from an independent experimental set. As shown in Figure 7B, exposure to c.m. from untreated RBL-2H3 cells induced a robust neurotoxic effect, significantly decreasing NeuN fluorescence intensity relative to control slices. Crucially, direct co-treatment with 50 nM PEA completely prevented this loss, successfully maintaining NeuN fluorescence intensity at baseline levels.

Astrocyte reactivity was evaluated by quantifying GFAP immunofluorescence in the dorsal horn. As shown in Figures 7D and 7E, exposure to untreated RBL-2H3 c.m. was associated with a significant reduction in GFAP fluorescence intensity. In contrast, slices co-treated with PEA and untreated RBL-2H3 c.m. exhibited a marked increase in GFAP signal compared with the untreated c.m. condition, effectively preventing this loss.



499

500 **Figure 7. Neuronal and astrocytic marker modulation in organotypic spinal cord slices exposed to mast cell-**
 501 **conditioned medium and PEA.**

502 *Immunofluorescence analysis of the neuronal marker (NeuN) and astrocytic marker (GFAP) in rat organotypic*
 503 *spinal cord slice cultures exposed to mast cell c.m. in the absence or presence of ultramicronized PEA (50 nM).*

504 Slices were treated with c.m. from untreated RBL-2H3 cells alone or in combination with PEA for 6 hours.
505 Slices were then washed and maintained in fresh medium for an additional 18 h before immunofluorescence
506 analysis. (A) Quantification of NeuN⁺ cell number in the dorsal horn. (B) Quantification of NeuN fluorescence
507 intensity in the dorsal horn (C) Representative images of NeuN immunofluorescence. (D) Quantification of
508 GFAP fluorescence intensity in the dorsal horn. (E) Representative images of GFAP immunofluorescence.
509 Images were acquired using a 20× objective; scale bar = 100 μm. Data are expressed as mean ± S.E.M. of three
510 independent experiments, with n = 14 or 15 slices per condition. **P < 0.01 vs CTR; ^P < 0.01, ^^P < 0.001
511 vs slices exposed to c.m. untreated RBL.

512

513 4. Discussion

514

515 The present study demonstrates that mast cell-derived mediators critically shape the neuroimmune
516 environment of the spinal cord both in basal conditions and morphine exposure. Moreover, it shows
517 that ultramicrosized PEA effectively orchestrates a dual-level modulation of this crosstalk within a
518 complex multicellular context, acting both upstream on mast cell secretory phenotypes and
519 downstream directly within neural tissue. Exposure of organotypic spinal cord slices to conditioned
520 medium derived from degranulated RBL-2H3 cells was sufficient to trigger a coordinated
521 neuroinflammatory response. The findings align with previous studies indicating mast cells as
522 regulators of the spinal neuroimmune milieu through the release of soluble mediators capable of
523 shaping neuronal-glial communication and tissue homeostasis [9,27–29]. Accordingly, the robust
524 upregulation of IL-6, IL-1β, CCL2 and PTX3 is consistent with established evidence that mast cell-
525 derived soluble factors activate innate immune signaling and promote central sensitization. In the
526 dorsal horn, cytokines like IL-1β and IL-6 directly enhance excitatory synaptic transmission, while
527 CCL2/CCR2 signaling drives microglia activation and amplifies persistent pain loops [30–32].
528 At a functional level, mast cell-derived factors significantly stimulated the release of CGRP from
529 spinal cord slices. Beyond its classical role in nociceptive neurotransmission, CGRP serves as a potent

530 neuroimmune amplifier by activating intracellular cascades in spinal glia, thereby sustaining chronic
531 neuroinflammatory states and persistent pain [33–36]. The increase in CGRP observed in our model
532 therefore supports the idea that mast cell-derived mediators are sufficient to engage pro-nociceptive
533 neuroimmune pathways in intact spinal tissue.

534 Notably, morphine reduced CGRP release, consistent with its canonical analgesic action. In
535 morphine-exposed slices, mast cell-conditioned medium did not increase CGRP release, suggesting
536 that opioid signaling modifies the spinal response to mast cell-derived mediators. Conditioned
537 medium from PEA-treated mast cells further reduced CGRP release, indicating that modulation of
538 the mast cell secretome can restrain pro-nociceptive signaling. These findings support a context-
539 dependent interaction between opioids and immune-derived signals [4,37].

540 Furthermore, our data reveal that this immune-neural disruption impairs cellular and network
541 homeostasis. Alterations in NeuN immunoreactivity likely reflect changes in neuronal functional state
542 and synaptic network integrity rather than overt neuronal loss, consistent with previous studies using
543 organotypic spinal cord cultures exposed to inflammatory stimuli [21]. Concurrently, changes in
544 GFAP expression and glial glutamate transporters EAAT1 and EAAT2 suggest a severe collapse of
545 astrocyte-mediated homeostatic mechanisms in response to mast cell mediators. Because astrocytes
546 are strictly required to clear extracellular glutamate, a reduction in EAAT2 expression leads to
547 extrasynaptic glutamate spillover, promoting excitotoxicity, and sustaining central sensitization and
548 chronic pain [38–40]. Together, these findings indicate that conditioned medium from activated mast
549 cells induces a neuroinflammatory and pro-nociceptive phenotype characterized by impaired neuron-
550 astrocyte homeostasis.

551 While morphine alone produced relatively modest changes in spinal cord slices, its presence markedly
552 exacerbated the effects of mast cell-conditioned medium. Morphine is increasingly recognized to
553 engage neuroimmune mechanisms beyond its direct neuronal actions, particularly through glial
554 activation and inflammatory signaling pathways [8,41,42]. In our model, the combination of
555 morphine and mast cell mediators resulted in enhanced inflammatory gene expression, further

dysregulation of astrocytic markers and altered glutamate transporter expression, indicating that morphine creates a permissive environment that amplifies immune-derived signaling. Within this inflammatory and morphine-sensitized context, ultramicrosized PEA exerted a definitive pro-homeostatic rescue via a sophisticated, dual-level mechanism. Upstream, PEA pre-treatment successfully reprogrammed the mast cell secretory activity. This observation is highly consistent with the autacoid local injury antagonism (ALIA) mechanism originally proposed by the Nobel laureate Rita Levi Montalcini [43], as well as with previous findings by our group [18]. Secretome analysis validated that PEA reduces the release of factors associated with mast cell activation, most notably the chemokine CCL2, a key regulator of neuroimmune communication in the spinal cord [44,45]. Downstream, direct application of PEA (50 nM) to the spinal slices efficiently intercepted neuroinflammatory cascades even after mast cell degranulation. Tissue-level PEA treatment strongly suppressed the transcription of IL-6, CCL2, and PTX3. These findings align with prior *in vivo* evidence demonstrating that PEA, reaching central nervous system structures [16], reduces inflammatory amplification in the injured spinal cord by limiting mast cell activation/infiltration and glial activation [46]. Furthermore, they parallel *ex vivo* data showing that PEA restrains spinal inflammatory enzymes and preserves neuronal readouts in multicellular spinal tissue preparations [47].

Functionally, ultramicrosized PEA normalized CGRP release under inflammatory conditions without affecting baseline levels. This context-dependent effect is consistent with its ability to reduce the pathological neuroimmune and glial activation, and the production of inflammatory mediators in models of neuropathic and inflammatory pain, thereby attenuating central sensitization [13,28,48–50].

At the cellular level, PEA restored GFAP expression and normalized EAAT1 and EAAT2 profiles, suggesting the recovery of astrocyte-mediated glutamate homeostasis. As reported by Scuderi et al. (2012), PEA modulates astrocyte reactivity through PPAR- α -dependent mechanisms, as well as preserves the NeuN immunoreactivity supporting a stabilization of the neuroimmune environment

582 primarily acting on non-neuronal cells, such as mast cells and glia [13,51].

583 To better characterize the molecular landscape of spinal response to morphine, mast cell-derived
584 factors and PEA, a quantitative proteomic analysis was performed, providing insight into coordinated
585 changes across inflammatory, structural and homeostatic pathways.

586 Morphine alone induced a limited but biologically meaningful proteomic shift, characterized by
587 upregulation of proteins involved in cytoskeletal regulation and immune signaling. One of them,
588 PFN1 has been implicated in actin dynamics and inflammatory polarization of microglia, with PFN1
589 suppression shown to inhibit M1-like pro-inflammatory microglial states while promoting anti-
590 inflammatory phenotypes [52,53]. Concurrently, morphine also increased RBM3 and DYNLRB1,
591 which have been associated with cellular stress responses, neuronal survival and adaptive plasticity
592 [54,55], suggesting the coexistence of early compensatory mechanisms that may nevertheless be
593 insufficient to counterbalance inflammatory signaling.

594 Exposure of control slices to conditioned medium derived from activated mast cells produced a much
595 broader proteomic remodeling, strongly skewed toward inflammatory and ECM-destabilizing
596 pathways. Among the upregulated proteins, CTSD and BGN are of particular interest. CTSD has
597 been shown to amplify neuroinflammation through activation of NF- κ B signaling in microglia [56],
598 while BGN functions as a damage-associated molecular pattern that activates TLR2 and TLR4
599 signaling, driving p38, ERK and NF- κ B-dependent inflammatory cascades [57,58]. The concomitant
600 downregulation of collagen type I chains in this condition suggests ECM remodeling toward a less
601 stable microenvironment, consistent with recent evidence indicating that disruption of collagen-rich
602 ECM contributes to CNS vulnerability and inflammatory amplification [59]. Together, these data
603 support the view that mast cell mediators promote a feed-forward loop of neuroinflammation and
604 matrix destabilization.

605 Strikingly, when spinal cord slices were exposed to conditioned medium from PEA-pretreated mast
606 cells, this inflammatory signature was substantially reshaped. The proteomic profile was
607 characterized by reduced expression of inflammatory ECM-associated mediators, such as BGN, and

608 increased expression of proteins associated with astrocytic regulation, including GFAP. This
609 observation is highly consistent with our previous findings in primary astrocyte cultures, where PEA-
610 conditioned mast cell media shifted astrocytes toward a less pro-inflammatory phenotype [18]. Given
611 the role of astrocytes in buffering inflammatory signals and maintaining tissue homeostasis, these
612 data suggest that ultramicrosized PEA indirectly promotes a more regulated glial environment by
613 modifying mast cell outputs.

614 Co-exposure to morphine and conditioned medium from activated mast cells generated a highly
615 deleterious proteomic signature characterized by extensive downregulation of ECM components,
616 including collagen VI chains (COL6A1, 2, 3). Collagen VI is increasingly recognized as a
617 neuroprotective ECM component that regulates autophagy, oxidative stress and cell survival; its loss
618 severely enhances neuronal vulnerability and accelerates neurodegeneration [60,61]. This matrix
619 destabilization was coupled with the upregulation of BIN1, a known orchestrator of pro-inflammatory
620 microglial phenotype transitions [62], further supporting the idea that morphine amplifies mast cell-
621 driven neuroinflammation.

622 Notably, exposure of morphine-treated slices to conditioned media from PEA-treated mast cells
623 reshaped this microenvironment, inducing a robust upregulation of protective ECM components,
624 including a complete rescue of collagen VI and increased levels of anti-inflammatory proteins, like
625 LGALS1. LGALS1 has been shown to directly suppress TNF- α -induced oxidative stress, promote
626 protective M2-like microglial polarization, and actively inhibit IgE-mediated mast cell activation
627 [63,64], representing a powerful counter-regulatory safety mechanism. The concomitant
628 downregulation of SIRT2 is also highly relevant, as SIRT2 has been implicated in neurodegenerative
629 processes and its inhibition confers neuroprotection in several disease models [65]. Moreover, the
630 suppression of SIRT2 reduces Fc ϵ RI-dependent mast cell degranulation [66], providing a multi-level
631 dampening of mast cell-driven inflammatory loop.

632 When applied directly to nervous tissue, ultramicrosized PEA also reduced the mast cell-driven
633 increase in CGRP release, restoring values toward baseline while leaving CGRP unchanged in control

634 slices. This pattern is compatible with a pro-homeostatic rather than suppressive profile and aligns
635 with electrophysiological evidence that PEA can inhibit nociceptive-evoked responses of dorsal horn
636 wide-dynamic-range neurons at the spinal level [67]. Finally, the accompanying changes in NeuN
637 and GFAP immunoreactivity suggest that PEA mitigates mast cell-induced perturbations of neuronal
638 marker expression and astrocytic activation, supporting the interpretation that PEA pro-
639 homeostatically modulates the neuroimmune microenvironment of the dorsal horn during
640 inflammatory challenge rather than acting as a generic neuronal suppressant [46].

641 In conclusion, our findings suggest that ultramicrosized PEA may play a vital dual role within the
642 spinal neuroimmune interface. By acting both upstream to blunt the primary mast cell inflammatory
643 output and downstream to protect spinal dorsal horn architectures from ongoing inflammatory
644 challenges, PEA appears to preserve the physiological crosstalk within the neuron-glia-matrix
645 network. This integrated mechanism provides a solid translational rationale for incorporating
646 ultramicrosized PEA as a potential adjunctive strategy to counteract neuroimmune maladaptation and
647 matrix destabilization. Beyond conceivably sustaining target drug efficacy, such as mitigating
648 morphine-induced dysregulation, this dual-level control offers a promising approach to modulate the
649 development of central sensitization, thereby opening new clinical avenues for the management of
650 chronic and neuroinflammatory pain states.

651

652 **Acknowledgments:** Not applicable

653

654 **Conflict of interest**

655 The authors declare that they have no known competing financial interests or personal relationships
656 that could have appeared to influence the work reported in this paper. Carla Ghelardini and Lorenzo
657 Di Cesare Mannelli received a grant from Epitech (Padua, Italy).

658

659 **Author Contributions**

660 AT: data curation, formal analysis, methodology, writing – original draft. MGC: data curation, formal
661 analysis, methodology, writing – original draft. LM: conceptualization, visualization, writing and
662 editing; EL: visualization, writing and editing; FM: formal analysis and methodology; DV: formal
663 analysis and methodology; GA: formal analysis and methodology. AD: formal analysis, methodology
664 and writing. TM: formal analysis, methodology, writing and editing. CG: conceptualization, funding
665 acquisition, supervision, writing and editing. LDCM: conceptualization, funding acquisition,
666 supervision, writing and editing.

667

668 **Co-author details**

669 Maria Giovanna Cataldi: mariagiovanna.cataldi@unifi.it, ORCID: 0009-0003-3016-5834

670 Laura Micheli: laura.micheli@unifi.it, ORCID: 0000-0002-6806-3222

671 Elena Lucarini: elena.lucarini@unifi.it, ORCID: 0000-0002-3459-2660

672 Francesco Margiotto: f.margiotto@ebris.eu, francesco.margiotto@unifi.it, ORCID: 0000-0002-6608-
673 5399

674 Daniel Venturi: daniel.venturi@ndcn.ox.ac.uk, daniel.venturi1@unifi.it, ORCID: 0009-0006-3933-
675 0236

676 Gilda Aiello: gilda.aiello@uniroma5.it, ORCID: 0000-0003-4327-0521

677 Alfonsina D'Amato: alfonsina.damato@unimi.it, ORCID: 0000-0002-8147-7235

678 Tommaso Mello: tommaso.mello@unifi.it, ORCID: 0000-0002-6192-6902

679 Carla Ghelardini: carla.ghelardini@unifi.it, ORCID: 0000-0001-9856-8144

680 Lorenzo Di Cesare Mannelli: lorenzo.mannelli@unifi.it, ORCID: 0000-0001-8374-4432

681

682 **Availability of data and material**

683 The data that support the findings of this study are available from the corresponding author on
684 reasonable request.

685

686 **Funding**

687 This work was supported by the European Union - NextGenerationEU - National Recovery and
688 Resilience Plan, Mission 4 Component 2 - Investment 1.4 – Strengthening research facilities and creation
689 of “Campioni Nazionali di R&S” on Key Enabling Technologies - National Center for Gene Therapy
690 and Drugs based on RNA Technology - CN000000041 - CUP B13C22001010001; by National Recovery
691 and Resilience Plan, project MNESYS (PE000000006) – A Multiscale integrated approach to the study
692 of the nervous system in health and disease (DN. 1553 11.10.2022) and the Italian Ministry of University
693 and Research (MIUR).

694

695 **Declaration of AI-assisted language editing**

696 During the preparation of this manuscript, the author used an artificial-intelligence-based tool solely for
697 the purpose of editing the English language (grammar, style, clarity). No generative AI was used to
698 create, analyze or interpret the scientific content of the work. All final wording, arguments, data
699 interpretation and conclusions remain entirely the responsibility of the authors.

700

701 **References**

- 702 1. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International
703 Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain*.
704 2020;161:1976–82. <https://doi.org/10.1097/j.pain.0000000000001939>
- 705 2. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain.
706 *Cell*. 2009;139:267–84. <https://doi.org/10.1016/j.cell.2009.09.028>
- 707 3. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. *Pain*.
708 2011;152:S2–15. <https://doi.org/10.1016/j.pain.2010.09.030>
- 709 4. Grace PM, Hutchinson MR, Maier SF, Watkins LR. Pathological pain and the neuroimmune

710 interface. *Nat Rev Immunol.* 2014;14:217–31. <https://doi.org/10.1038/nri3621>

711 5. Lambert DG. Opioids and opioid receptors; understanding pharmacological mechanisms as a key
712 to therapeutic advances and mitigation of the misuse crisis. *BJA Open.* 2023;6:100141.
713 <https://doi.org/10.1016/j.bjao.2023.100141>

714 6. Roeckel L-A, Utard V, Reiss D, Mouheiche J, Maurin H, Robé A, et al. Morphine-induced
715 hyperalgesia involves mu opioid receptors and the metabolite morphine-3-glucuronide. *Sci Rep.*
716 2017;7:10406. <https://doi.org/10.1038/s41598-017-11120-4>

717 7. Zhou J, Ma R, Jin Y, Fang J, Du J, Shao X, et al. Molecular mechanisms of opioid tolerance:
718 From opioid receptors to inflammatory mediators (Review). *Exp Ther Med.* 2021;22:1004.
719 <https://doi.org/10.3892/etm.2021.10437>

720 8. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial
721 activation: mechanisms of activation and implications for opioid analgesia, dependence, and
722 reward. *ScientificWorldJournal.* 2007;7:98–111. <https://doi.org/10.1100/tsw.2007.230>

723 9. Mittal A, Sagi V, Gupta M, Gupta K. Mast Cell Neural Interactions in Health and Disease. *Front*
724 *Cell Neurosci.* 2019;13:110. <https://doi.org/10.3389/fncel.2019.00110>

725 10. Polyzoidis S, Koletsa T, Panagiotidou S, Ashkan K, Theoharides TC. Mast cells in
726 meningiomas and brain inflammation. *J Neuroinflammation.* 2015;12:170.
727 <https://doi.org/10.1186/s12974-015-0388-3>

728 11. Levy D. Migraine pain, meningeal inflammation, and mast cells. *Curr Pain Headache Rep.*
729 2009;13:237–40. <https://doi.org/10.1007/s11916-009-0040-y>

730 12. Varrassi G, Fusco M, Skaper SD, Battelli D, Zis P, Coaccioli S, et al. A Pharmacological
731 Rationale to Reduce the Incidence of Opioid Induced Tolerance and Hyperalgesia: A Review. *Pain*

732 Ther. 2018;7:59–75. <https://doi.org/10.1007/s40122-018-0094-9>

733 13. Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the
734 therapeutic efficacy of some of its new formulations. *Br J Pharmacol.* 2017;174:1349–65.
735 <https://doi.org/10.1111/bph.13580>

736 14. Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E, et al.
737 Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to
738 nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. *J Neuroinflammation.*
739 2014;11:136. <https://doi.org/10.1186/s12974-014-0136-0>

740 15. Nobili S, Micheli L, Lucarini E, Toti A, Ghelardini C, Di Cesare Mannelli L. Ultramicronized
741 N-palmitoylethanolamine associated with analgesics: Effects against persistent pain. *Pharmacol*
742 *Ther.* 2024;258:108649. <https://doi.org/10.1016/j.pharmthera.2024.108649>

743 16. Petrosino S, Cordaro M, Verde R, Schiano Moriello A, Marcolongo G, Schievano C, et al. Oral
744 Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic
745 Effect. *Front Pharmacol.* 2018;9:249. <https://doi.org/10.3389/fphar.2018.00249>

746 17. Di Cesare Mannelli L, Micheli L, Lucarini E, Ghelardini C. Ultramicronized N-
747 Palmitoylethanolamine Supplementation for Long-Lasting, Low-Dosed Morphine Antinociception.
748 *Front Pharmacol.* 2018;9:473. <https://doi.org/10.3389/fphar.2018.00473>

749 18. Toti A, Micheli L, Lucarini E, Ferrara V, Ciampi C, Margiotta F, et al. Ultramicronized N-
750 Palmitoylethanolamine Regulates Mast Cell-Astrocyte Crosstalk: A New Potential Mechanism
751 Underlying the Inhibition of Morphine Tolerance. *Biomolecules.* 2023;13:233.
752 <https://doi.org/10.3390/biom13020233>

753 19. Micheli L, Lucarini E, Nobili S, Bartolucci G, Pallecchi M, Toti A, et al. Ultramicronized N-
754 palmitoylethanolamine Contributes to Morphine Efficacy Against Neuropathic Pain: Implication of

755 Mast Cells and Glia. *Curr Neuroparmacol*. 2024;22:88–106.
 756 <https://doi.org/10.2174/1570159X21666221128091453>

757 20. Humpel C. Organotypic brain slice cultures: A review. *Neuroscience*. 2015;305:86–98.
 758 <https://doi.org/10.1016/j.neuroscience.2015.07.086>

759 21. Ravikumar M, Jain S, Miller RH, Capadona JR, Selkirk SM. An organotypic spinal cord slice
 760 culture model to quantify neurodegeneration. *J Neurosci Methods*. 2012;211:280–8.
 761 <https://doi.org/10.1016/j.jneumeth.2012.09.004>

762 22. McGrath JC, Lilley E. Implementing guidelines on reporting research using animals (ARRIVE
 763 etc.): new requirements for publication in BJP. *Br J Pharmacol*. 2015;172:3189–93.
 764 <https://doi.org/10.1111/bph.12955>

765 23. Toti A, Lucarini E, Ferrara V, Parisio C, Ciampi C, Gerace E, et al. The dual role of VEGF-A in
 766 a complex in vitro model of oxaliplatin-induced neurotoxicity: Pain-related and neuroprotective
 767 effects. *Neurotherapeutics*. 2025;22:e00532. <https://doi.org/10.1016/j.neurot.2025.e00532>

768 24. D’Amato A, Di Cesare Mannelli L, Lucarini E, Man AL, Le Gall G, Branca JJV, et al. Faecal
 769 microbiota transplant from aged donor mice affects spatial learning and memory via modulating
 770 hippocampal synaptic plasticity- and neurotransmission-related proteins in young recipients.
 771 *Microbiome*. 2020;8:140. <https://doi.org/10.1186/s40168-020-00914-w>

772 25. Radrezza S, Carini M, Baron G, Aldini G, Negre-Salvayre A, D’Amato A. Study of Carnosine’s
 773 effect on nude mice skin to prevent UV-A damage. *Free Radic Biol Med*. 2021;173:97–103.
 774 <https://doi.org/10.1016/j.freeradbiomed.2021.07.010>

775 26. Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free
 776 quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ.
 777 *Mol Cell Proteomics*. 2014;13:2513–26. <https://doi.org/10.1074/mcp.M113.031591>

- 778 27. Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation
779 – or should it be mast cell mediator disorders? *Expert Rev Clin Immunol.* 2019;15:639–56.
780 <https://doi.org/10.1080/1744666X.2019.1596800>
- 781 28. Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide,
782 a naturally occurring disease-modifying agent in neuropathic pain. *Inflammopharmacology.*
783 2014;22:79–94. <https://doi.org/10.1007/s10787-013-0191-7>
- 784 29. Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. Mast cell degranulation activates
785 a pain pathway underlying migraine headache. *Pain.* 2007;130:166–76.
786 <https://doi.org/10.1016/j.pain.2007.03.012>
- 787 30. Kawasaki Y, Zhang L, Cheng J-K, Ji R-R. Cytokine mechanisms of central sensitization:
788 distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in
789 regulating synaptic and neuronal activity in the superficial spinal cord. *J Neurosci.* 2008;28:5189–
790 94. <https://doi.org/10.1523/JNEUROSCI.3338-07.2008>
- 791 31. White FA, Bhangoo SK, Miller RJ. Chemokines: integrators of pain and inflammation. *Nat Rev*
792 *Drug Discov.* 2005;4:834–44. <https://doi.org/10.1038/nrd1852>
- 793 32. Fan M, Liang Z, Shen J, Yang H, Zhao L, Li M, et al. The function of chemokine-driven glial-
794 neuronal interaction in chronic pain. *Front Neurosci.* 2026;20:1830053.
795 <https://doi.org/10.3389/fnins.2026.1830053>
- 796 33. Russell FA, King R, Smillie S-J, Kodji X, Brain SD. Calcitonin gene-related peptide:
797 physiology and pathophysiology. *Physiol Rev.* 2014;94:1099–142.
798 <https://doi.org/10.1152/physrev.00034.2013>
- 799 34. Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral
800 and central pain mechanisms including migraine. *Pain.* 2017;158:543–59.

801 <https://doi.org/10.1097/j.pain.0000000000000831>

802 35. Wang Z, Ma W, Chabot J-G, Quirion R. Calcitonin gene-related peptide as a regulator of
803 neuronal CaMKII-CREB, microglial p38-NFκB and astroglial ERK-Stat1/3 cascades mediating the
804 development of tolerance to morphine-induced analgesia. *Pain*. 2010;151:194–205.
805 <https://doi.org/10.1016/j.pain.2010.07.006>

806 36. Ji R-R, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and Central
807 Sensitization in Chronic and Widespread Pain. *Anesthesiology*. 2018;129:343–66.
808 <https://doi.org/10.1097/ALN.0000000000002130>

809 37. Bannister K, Dickenson AH. What the brain tells the spinal cord. *Pain*. 2016;157:2148–51.
810 <https://doi.org/10.1097/j.pain.0000000000000568>

811 38. Di Cesare Mannelli L, Pacini A, Micheli L, Tani A, Zanardelli M, Ghelardini C. Glial role in
812 oxaliplatin-induced neuropathic pain. *Exp Neurol*. 2014;261:22–33.
813 <https://doi.org/10.1016/j.expneurol.2014.06.016>

814 39. Nie H, Weng H-R. Impaired glial glutamate uptake induces extrasynaptic glutamate spillover in
815 the spinal sensory synapses of neuropathic rats. *J Neurophysiol*. 2010;103:2570–80.
816 <https://doi.org/10.1152/jn.00013.2010>

817 40. Popiolek-Barczyk K, Mika J. Targeting the Microglial Signaling Pathways: New Insights in the
818 Modulation of Neuropathic Pain. *Curr Med Chem*. 2016;23:2908–28.
819 <https://doi.org/10.2174/0929867323666160607120124>

820 41. Di Cesare Mannelli L, Corti F, Micheli L, Zanardelli M, Ghelardini C. Delay of morphine
821 tolerance by palmitoylethanolamide. *Biomed Res Int*. 2015;2015:894732.
822 <https://doi.org/10.1155/2015/894732>

- 823 42. Yang Y, Sun Y, Hu R, Yan J, Wang Z, Li W, et al. Morphine promotes microglial activation by
824 upregulating the EGFR/ERK signaling pathway. *PLoS One*. 2021;16:e0256870.
825 <https://doi.org/10.1371/journal.pone.0256870>
- 826 43. Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte
827 behaviour. *Agents Actions*. 1993;39 Spec No:C145-147. <https://doi.org/10.1007/BF01972748>
- 828 44. Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK, et al. Impaired
829 neuropathic pain responses in mice lacking the chemokine receptor CCR2. *Proc Natl Acad Sci U S*
830 *A*. 2003;100:7947–52. <https://doi.org/10.1073/pnas.1331358100>
- 831 45. Zhang J, Shi XQ, Echeverry S, Mogil JS, De Koninck Y, Rivest S. Expression of CCR2 in both
832 resident and bone marrow-derived microglia plays a critical role in neuropathic pain. *J Neurosci*.
833 2007;27:12396–406. <https://doi.org/10.1523/JNEUROSCI.3016-07.2007>
- 834 46. Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, et al. Effects of
835 palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord
836 injury. *Brain Behav Immun*. 2011;25:1099–112. <https://doi.org/10.1016/j.bbi.2011.02.006>
- 837 47. Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, Esposito E. A new co-
838 ultramicronized composite including palmitoylethanolamide and luteolin to prevent
839 neuroinflammation in spinal cord injury. *J Neuroinflammation*. 2013;10:91.
840 <https://doi.org/10.1186/1742-2094-10-91>
- 841 48. Di Cesare Mannelli L, D'Agostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C, et al.
842 Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and
843 Neuroprotection Share a PPAR-Alpha-Mediated Mechanism. *Mediators Inflamm*.
844 2013;2013:328797. <https://doi.org/10.1155/2013/328797>
- 845 49. Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, et al.

846 Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model
847 of Alzheimer's disease. *Cell Death Dis.* 2014;5:e1419. <https://doi.org/10.1038/cddis.2014.376>

848 50. Di Cesare Mannelli L, Pacini A, Corti F, Boccella S, Luongo L, Esposito E, et al.
849 Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced
850 neurotoxicity. *PLoS One.* 2015;10:e0128080. <https://doi.org/10.1371/journal.pone.0128080>

851 51. Scuderi C, Valenza M, Stecca C, Esposito G, Carratù MR, Steardo L. Palmitoylethanolamide
852 exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via
853 peroxisome proliferator-activated receptor- α . *J Neuroinflammation.* 2012;9:49.
854 <https://doi.org/10.1186/1742-2094-9-49>

855 52. Lu E, Wang Q, Li S, Chen C, Wu W, Xu YXZ, et al. Profilin 1 knockdown prevents ischemic
856 brain damage by promoting M2 microglial polarization associated with the RhoA/ROCK pathway.
857 *J Neurosci Res.* 2020;98:1198–212. <https://doi.org/10.1002/jnr.24607>

858 53. Pereira GRC, Tellini GHAS, De Mesquita JF. In silico analysis of PFN1 related to amyotrophic
859 lateral sclerosis. *PLoS One.* 2019;14:e0215723. <https://doi.org/10.1371/journal.pone.0215723>

860 54. Pilotte J, Kiosses W, Chan SW, Makarenkova HP, Dupont-Versteegden E, Vanderklish PW.
861 Morphoregulatory functions of the RNA-binding motif protein 3 in cell spreading, polarity and
862 migration. *Sci Rep.* 2018;8:7367. <https://doi.org/10.1038/s41598-018-25668-2>

863 55. Terenzio M, Di Pizio A, Rishal I, Marvaldi L, Di Matteo P, Kawaguchi R, et al. DYNLRB1 is
864 essential for dynein mediated transport and neuronal survival. *Neurobiol Dis.* 2020;140:104816.
865 <https://doi.org/10.1016/j.nbd.2020.104816>

866 56. Gan P, Xia Q, Hang G, Zhou Y, Qian X, Wang X, et al. Knockdown of cathepsin D protects
867 dopaminergic neurons against neuroinflammation-mediated neurotoxicity through inhibition of NF-
868 κ B signalling pathway in Parkinson's disease model. *Clin Exp Pharmacol Physiol.* 2019;46:337–49.

869 <https://doi.org/10.1111/1440-1681.13052>

870 57. Schaefer L, Babelova A, Kiss E, Hausser H-J, Baliova M, Krzyzankova M, et al. The matrix
871 component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in
872 macrophages. *J Clin Invest.* 2005;115:2223–33. <https://doi.org/10.1172/JCI23755>

873 58. Roedig H, Nastase MV, Wygrecka M, Schaefer L. Breaking down chronic inflammatory
874 diseases: the role of biglycan in promoting a switch between inflammation and autophagy. *FEBS J.*
875 2019;286:2965–79. <https://doi.org/10.1111/febs.14791>

876 59. Wareham LK, Baratta RO, Del Buono BJ, Schlumpf E, Calkins DJ. Collagen in the central
877 nervous system: contributions to neurodegeneration and promise as a therapeutic target. *Mol*
878 *Neurodegener.* 2024;19:11. <https://doi.org/10.1186/s13024-024-00704-0>

879 60. Chen P, Cescon M, Megighian A, Bonaldo P. Collagen VI regulates peripheral nerve
880 myelination and function. *FASEB J.* 2014;28:1145–56. <https://doi.org/10.1096/fj.13-239533>

881 61. Cescon M, Chen P, Castagnaro S, Gregorio I, Bonaldo P. Lack of collagen VI promotes
882 neurodegeneration by impairing autophagy and inducing apoptosis during aging. *Aging (Albany*
883 *NY).* 2016;8:1083–101. <https://doi.org/10.18632/aging.100924>

884 62. Sudwarts A, Ramesha S, Gao T, Ponnusamy M, Wang S, Hansen M, et al. BIN1 is a key
885 regulator of proinflammatory and neurodegeneration-related activation in microglia. *Mol*
886 *Neurodegener.* 2022;17:33. <https://doi.org/10.1186/s13024-022-00535-x>

887 63. Aalinkeel R, Mangum CS, Abou-Jaoude E, Reynolds JL, Liu M, Sundquist K, et al. Galectin-1
888 Reduces Neuroinflammation via Modulation of Nitric Oxide-Arginase Signaling in HIV-1
889 Transfected Microglia: a Gold Nanoparticle-Galectin-1 “Nanoplex” a Possible Neurotherapeutic? *J*
890 *Neuroimmune Pharmacol.* 2017;12:133–51. <https://doi.org/10.1007/s11481-016-9723-4>

- 891 64. Yang L-T, Shu Q, Luo X-Q, Liu Z-Q, Qiu S-Q, Liu J-Q, et al. Long-term effects: Galectin-1
892 and specific immunotherapy for allergic responses in the intestine. *Allergy*. 2018;73:106–14.
893 <https://doi.org/10.1111/all.13256>
- 894 65. Donmez G, Outeiro TF. SIRT1 and SIRT2: emerging targets in neurodegeneration. *EMBO Mol*
895 *Med*. 2013;5:344–52. <https://doi.org/10.1002/emmm.201302451>
- 896 66. Kim Y-Y, Hur G, Lee SW, Lee S-J, Lee S, Kim S-H, et al. AGK2 ameliorates mast cell-
897 mediated allergic airway inflammation and fibrosis by inhibiting FcεRI/TGF-β signaling pathway.
898 *Pharmacol Res*. 2020;159:105027. <https://doi.org/10.1016/j.phrs.2020.105027>
- 899 67. González-Hernández A, Martínez-Lorezana G, Rodríguez-Jiménez J, Rojas-Piloni G, Condés-
900 Lara M. Intracisternal injection of palmitoylethanolamide inhibits the peripheral nociceptive evoked
901 responses of dorsal horn wide dynamic range neurons. *J Neural Transm (Vienna)*. Vienna, Austria :
902 1996; 2015;122:369–74. <https://doi.org/10.1007/s00702-014-1255-6>

903

904 **Notes**

905 The images shown in the figures panels to illustrate immunofluorescence data were processed using
906 the Thunder algorithm (Leica Software) to reduce background noise. Entire Thunder-processed
907 images were subsequently adjusted for contrast and brightness to improve presentation clarity.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryMaterial.docx](#)